Trial Profile
Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nilotinib or Dasatinib therapy, "Bosutinib Dose Optimization Study - BODO-Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms BODO
- 01 Oct 2023 Results published in the Annals of Hematology
- 14 Dec 2021 Results of first and final analysis (n=57) assessing whether a bosutinib step-in dosing regimen decreases GI toxicity while maintaining optimal efficacy in patients (pts) with CML after failure or intolerance to 2G-TKIs presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 24 Jul 2020 Status changed from suspended to discontinued.